Serum levels of CXCL13 are elevated in active multiple sclerosis

Multiple Sclerosis

Volumn 15, Issue 11, 2009, Pages 1271-1279

  Festa, Eugene D ^a   Hankiewicz, Karolina ^b   Kim, Soyeon ^a   Skurnick, Joan ^a   Wolansky, Leo J ^a   Cook, Stuart D ^a   Cadavid, Diego ^a,c  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b HOSPITAL CLÍNIC   (Spain)

^c BIOGEN   (United States)

Author keywords

Biomarkers; Brain; CXCL13; MRI; Multiple sclerosis

Indexed keywords

CXCL13 CHEMOKINE; GADOLINIUM; GLATIRAMER; INTERFERON BETA SERINE;

ADULT; ARTICLE; B LYMPHOCYTE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; IMMUNOPATHOGENESIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION;

ADOLESCENT; ADULT; B-LYMPHOCYTES; BRAIN; CHEMOKINE CXCL13; DISABILITY EVALUATION; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE I, RECOMBINANT; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; OBSERVER VARIATION; PEPTIDES; YOUNG ADULT;

EID: 70450184483     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458509107017     Document Type: Article

References (28)

1. Miller DH, Rudge P., Johnson G., et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain 1988; 111: 927-39.
2. McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992; 32: 758-66.
3. Cadavid D., Wolansky LJ, Skurnick J., et al. Efficacy of treatment of MS with IFN{beta}-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 2009; 72: 1976-83.
4. Lucchinetti CF, Gavrilova RH, Metz I., et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 2008; 131: 1759-75.
5. Ransohoff RM, Liu L., Cardona AE Chemokines and chemokine receptors: multipurpose players in neuroinflammation. Int Rev Neurobiol 2007; 82: 187-204.
6. Krumbholz M., Theil D., Cepok M., et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 Up-regulation is differentially linked to CNS immune cell recruitment. Brain 2006; 129: 200-11.
7. Michalowska- Wender G., Losy J., Blernacka-Lukanty J., Wender M. Impact of methylprednisolone treatment on the expression of macrophage inflammatory protein 3alpha and B lymphocyte chemoattractant in serum of multiple sclerosis patients. Pharmacol Rep 2008; 60: 549-54.
8. Gunn MD, Ngo VN, Ansel KM, et al. A B-cell-homing chemokine made in lymphoid follicles activates burkitt's lymphoma receptor-1. Nature 1998; 391: 799-803.
9. Hauser SL, Waubant E., Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676-88.
10. Kurtzke JF Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
11. Rudick RA, Cutter G., Baier M., et al. Use of the multiple sclerosis functional composite to predict disability in relapsing MS. Neurology 2001; 56: 1324-30.
12. Kantor AB, Deng J., Waubant E., et al. Identification of short-term pharmacodynamic effects of interferon-beta-1a in multiple sclerosis subjects with broad-based phenotypic profiling. J Neuroimmunol 2007; 188: 103-16.
13. Kalkers NF, Bergers L., de Groot V., et al. Concurrent validity of the ms functional composite using MRI as a biological disease marker. Neurology 2001; 56: 215-9.
14. Widney DP, Breen EC, Boscardin WJ, et al. Serum levels of the homeostatic B cell chemokine, CXCL13, are elevated during HIV infection. J Interferon Cytokine Res 2005; 25: 702-6.
15. Burkle A., Niedermeier M., Schmitt-Graff A., et al. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood 2007; 110: 3316-25.
16. Rioja I., Hughes FJ, Sharp CH, et al. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Arthritis Rheum 2008; 58: 2257-67.
17. Londono D., Marques A., Hornung RL, Cadavid D., et al. Relapsing fever borreliosis in IL-10 deficient mice. Infect Immun 2008; 76: 5508-13.
18. Gelderblom H., Londono D., Bai Y., et al. High production of CXCL13 in blood and brain during persistent infection with the relapsing fever spirochete borrelia turicatae. J Neuropathol Exp Neurol 2007; 66: 208-17.
19. Cadavid D. The mammalian host response to borrelia infection. Wien Klin Wochenschr 2006; 118: 653-8.
20. Narayan K., Dali D., Li L., et al. The nervous system as ectopic germinal center: CXCL13 and IgG in lyme neuroborreliosis. Ann Neurol 2005; 57: 813-23.
21. Pachner AR, Dail D., Narayan K., Dutta K., Cadavid D., et al. Increased expression of B-lymphocyte chemoattractant, but not pro-inflammatory cytokines, in muscle tissue in rhesus chronic lyme borreliosis. Cytokine 2002; 19: 297-307.
22. Magliozzi R., Columba-Cabezas S., Serafini B., Aloisi F. Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol 2004; 148: 11-23.
23. Ljostad U., Mygland A. CSF B-lymphocyte chemoattractant (CXCL13) in the early diagnosis of acute lyme neuroborreliosis. J Neurol 2008; 255: 732-7.
24. Rupprecht TA, Pfister HW, Angele B., et al. The chemokine CXCL13 (BLC): a putative diagnostic marker for neuroborreliosis. Neurology 2005; 65: 448-50.
25. Columba-Cabezas S., Griguoli M., Rosicarelli B., et al. Suppression of established experimental autoimmune encephalomyelitis and formation of meningeal lymphoid follicles by lymphotoxin Beta Receptor-Ig fusion protein. J Neuroimmunol 2006; 179: 76-86.
26. Ukkonen M., Wu K., Reipert B., Dastidar P., Elovaara I. Cell surface adhesion molecules and cytokine profiles in primary progressive multiple sclerosis. Mult Scler 2007; 13: 701-7.
27. Bartosik-Psujek H., Stelmasiak Z. The levels of chemokines CXCL8, CCL2 and CCL5 in multiple sclerosis patients are linked to the activity of the disease. Eur J Neurol 2005; 12: 49-54.
28. Losy J., Michalowska-Wender G., Kurdynska A., Wender M. CCL2 (MCP-1) and CCL5 (RANTES) levels in the peripheral blood of multiple sclerosis patients treated with glatiramer acetate (Copaxone). Folia Neuropathol 2005; 43: 153-5.